Amgen's First EU Biosimilar Filing Targets AbbVie's Humira
This article was originally published in Scrip
Amgen has begun its incursion into the EU biosimilars market by filing an approval application with the European Medicines Agency for ABP 501, a version of AbbVie's blockbuster MAb Humira (adalimumab). This is the company's first biosimilar filing in Europe, and it believes it is also the first EU filing for a biosimilar Humira.
You may also be interested in...
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
The UK’s rapid authorization of the Pfizer/BioNTech COVID-19 vaccine has sparked a public debate over regulatory processes at some of the world’s key regulatory bodies.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.